Nucleus Software Exports Ltd (NSEL) was incorporated in Jan.'89 as Nucleus Software Exports Pvt Ltd and was subsequently converted into a Public Ltd in Oct.'94. Nucleus Software Exports Ltd is a global software company engaged in providing products and software solutions to the banking and financial services industry . It provides solutions for retail banking, corporate banking, cash management, Internet banking and credit cards. Its products include Finnone, Cash@will and BankOnet. Finnone provide suite for retail banking applications comprising of modules like customer acquisition system, loan management, delinquency and recovery management, deposits and finance against securities. 

Market Cap:  717.76 Crores

Recommended Price:  221.60

Current Price

Book Value:  142.55

Stock P/E: 11.09

Dividend Yield: 2.47%

Stock is  10.00 paid up

Listed on BSE & NSE

Company has reported a sales of 100.9 cr for march quarter 15 against 87.69 cr and net profit of 20.64 cr against 18.84 cr.
Company is virtually a debit free and high dividend paying.

One can buy stock @221 for long term gain.company listed in NSE and BSE.

The driving forces of Berger Paints – reflect the very spirit of its founder Lewis Berger – who laid the foundations of brand Berger way back in 1760 in the UK. With modest beginnings in India in 1923, today, Berger Paints India Limited is the second largest paint company in the country with a consistent track record of being one of  the fastest growing paint company, quarter on quarter, for the past few  years.

berger pains india ltd records a growth of 19.5% in revenues and 26.3% in profit after ax for the quarter ended 31st march 2014

net profit for march 2014 was 55.3 crore vs 43.8 crore agains corresponding quarter.

growth in revenue for the year was 15.6% and in profit afer tax was 14.2%.

recommends a dividend of 110% compared to 90% in the previous year.

recommending stock to buy @246 for long term gain.

link to company website:http://www.bergerpaints.com/

One of the leading manufacturers of Active Pharmaceutical Ingredients (API’s). Registered in 1960, the company has grown several folds and earned recognition besides gaining the trust of a strong customer base. Today it is one of the largest producers of macro ides in the country.

Anuh Pharma has reported a standalone sales turnover of Rs 76.61 crore and a net profit of Rs 5.69 crore for the quarter ended Mar ’14. Other income for the quarter was Rs 1.77 crore. For the quarter ended Mar 2013 the standalone sales turnover was Rs 58.92 crore and net profit was Rs 3.02 crore, and other income Rs 0.84 crore. Company declares 6.5INR dividend per equity share.

Stock is available @quiet attractive price as compared to peer group. One can buy stock for long term gain. Stock is available on base @182.

Current Price

Links to company website: http://www.anuhpharma.com/